Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.

Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E.

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e855. doi: 10.1371/journal.pntd.0000855.

2.

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.

Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J; Leishmaniasis East Africa Platform (LEAP) group..

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e709. doi: 10.1371/journal.pntd.0000709.

3.

Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.

Hamad SH, Khalil EA, Musa AM, Ibrahim ME, Younis BM, Elfaki ME, El-Hassan AM; Leishmaniasis Research Group, Sudan..

Exp Parasitol. 2010 Aug;125(4):389-93. doi: 10.1016/j.exppara.2010.03.008.

PMID:
20346944
4.
5.

The relationship between leishmaniasis and AIDS: the second 10 years.

Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J.

Clin Microbiol Rev. 2008 Apr;21(2):334-59, table of contents. doi: 10.1128/CMR.00061-07. Review.

6.

Development of a WHO growth reference for school-aged children and adolescents.

de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J.

Bull World Health Organ. 2007 Sep;85(9):660-7.

7.

Visceral leishmaniasis in eastern Africa--current status.

Reithinger R, Brooker S, Kolaczinski JH.

Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1169-70. Review.

9.

Injectable paromomycin for Visceral leishmaniasis in India.

Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.

N Engl J Med. 2007 Jun 21;356(25):2571-81.

10.

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.

Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.

Clin Infect Dis. 2006 Aug 1;43(3):357-64.

11.

Drug resistance in leishmaniasis.

Croft SL, Sundar S, Fairlamb AH.

Clin Microbiol Rev. 2006 Jan;19(1):111-26. Review.

12.

Sodium stibogluconate cardiotoxicity and safety of generics.

Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S.

Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):597-8.

PMID:
15307436
13.

Drug resistance in Indian visceral leishmaniasis.

Sundar S.

Trop Med Int Health. 2001 Nov;6(11):849-54. Erratum in: Trop Med Int Health 2002 Mar;7(3):293.

14.
15.

The medical dictionary for regulatory activities (MedDRA).

Brown EG, Wood L, Wood S.

Drug Saf. 1999 Feb;20(2):109-17. Review.

PMID:
10082069
16.

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S.

BMJ. 1998 Apr 18;316(7139):1200-5.

17.

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.

Chunge CN, Owate J, Pamba HO, Donno L.

Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):221-5.

PMID:
2167522
Items per page

Supplemental Content

Support Center